Wegovy 7.2mg: The Higher Dose That Could Close the Gap With Tirzepatide
Novo Nordisk has filed for FDA approval of a higher-dose Wegovy injection — 7.2mg once weekly, a significant step up from the current maximum of 2.4mg. The data behind it comes from the STEP-UP trial, and the numbers are noteworthy.
The STEP-UP Trial Results
The STEP-UP trial compared three groups at 72 weeks:
| Group | Weight Loss at 72 Weeks |
|---|---|
| Wegovy 7.2mg | 18.7% |
| Wegovy 2.4mg (current max) | 15.6% |
| Placebo | 3.9% |
The 3.1 percentage point gap between 7.2mg and 2.4mg is clinically meaningful. For a 250-pound man, that's roughly an additional 7.5 pounds of weight loss — the difference between losing 39 pounds and losing 47 pounds over 18 months.
Why This Matters: The Tirzepatide Comparison
One of semaglutide's persistent disadvantages has been its efficacy ceiling compared to tirzepatide (Zepbound/Mounjaro). At maximum doses, tirzepatide has shown weight loss of 19.5–20.9% — a gap that pushed many men and providers toward the dual-agonist medication.
Wegovy 7.2mg at 18.7% doesn't fully close that gap, but it narrows it substantially. For men who respond well to semaglutide, who prefer sticking with a medication they know, or who have insurance that covers Wegovy but not Zepbound, the higher dose offers a meaningful upgrade without switching molecules.
Who Benefits Most
Plateau patients: Men who hit a weight loss plateau on Wegovy 2.4mg are the primary candidates. Rather than switching to an entirely new medication, dose escalation with the same molecule offers a simpler path to additional results.
Men who tolerate semaglutide well: Some men experience fewer GI side effects on semaglutide compared to tirzepatide (or vice versa). For those who have found their stride on Wegovy, a higher dose keeps them in familiar territory.
Insurance considerations: Some plans cover Wegovy but not Zepbound. If a higher dose of a covered medication achieves comparable results, the insurance math works better.
What This Means for Compounded Semaglutide
Men currently on compounded semaglutide already have theoretical access to higher doses — compounding pharmacies are not limited to the branded dose caps. However, higher doses carry increased side effect risk (primarily nausea and GI symptoms), and dose escalation beyond 2.4mg should only happen under medical supervision with a provider who monitors response.
If your current provider offers dose flexibility and active management:
Ready to Get Started?
Compare telehealth providers offering GLP-1 prescriptions for men.
Compare Providers →